About Proteon
We are working to deliver a new future for patients and families affected by kidney and vascular diseases, where innovation drives health improvement and healthcare professionals have the tools they need to improve patient outcomes.
Overview
Proteon Therapeutics is a late-stage biopharmaceutical company committed to improving the lives of patients and families affected by kidney and vascular diseases. Our goal is to address some of the most urgent needs of patients by developing potentially transformative solutions that redefine how these diseases are treated. Our lead product candidate, vonapanitase, is a first-in-class, investigational drug intended to treat vessel injury that leads to blood vessel blockage and reduced blood flow. Vonapanitase is currently being evaluated in a pivotal Phase 3 clinical study in hemodialysis vascular access. Vonapanitase has received breakthrough, fast track and orphan drug designations from the U.S. Food and Drug Administration (FDA) and orphan medicinal product designation from the European Commission for hemodialysis vascular access indications.
For people with chronic kidney disease (CKD) requiring hemodialysis, a functioning vascular access is their lifeline to care, enabling connection to a dialysis machine three times per week for life-saving blood cleansing. The preferred form of vascular access is a radiocephalic arteriovenous fistula created in the forearm. Unfortunately, up to 40% of radiocephalic fistulas will be abandoned within one year of surgical creation and more than 50% will fail to be used for hemodialysis. The clinical consequences of fistula abandonment are severe, including a reduction in dialysis adequacy, one or more surgical procedures to create a new vascular access, and prolonged exposure to dialysis catheters, the worst form of vascular access due to the increased risk of infection, hospitalization and death. We are currently conducting a pivotal Phase 3 clinical trial evaluating whether a single topical administration of investigational vonapanitase can improve radiocephalic fistula outcomes. We are not aware of any products approved in the U.S. or Europe that would compete with vonapanitase for the improvement of secondary patency (time to abandonment) and fistula use for hemodialysis.
Vonapanitase is also being studied in patients with peripheral arterial disease (PAD). Patients with PAD suffer from a blockage in the arteries providing blood to the legs, which may result in impaired walking ability, leg pain and gangrene, and ultimately amputation. Many patients undergo invasive revascularization procedures to treat the blockage, but these procedures have poor long-term durability, resulting in the potential for repeat interventions, symptom recurrence and disease progression. Building on prior Phase 1 results, our current Phase 1 clinical trial is evaluating whether a single local administration of vonapanitase can reduce the symptoms of PAD in patients undergoing angioplasty of an artery below the knee.
Management Team
Timothy Noyes joined Proteon in 2006 as our President and Chief Executive Officer and has also been a member of our board of directors since joining the company. From 2002 to 2006, Mr. Noyes served as Chief Operating Officer of Trine Pharmaceuticals, Inc., a biopharmaceutical company. Before joining Trine, Mr. Noyes held several management positions with GelTex Pharmaceuticals from 1996 to 2001, prior to its acquisition by Genzyme Corporation. After the acquisition, from 2001 to 2002, he held the position of President, Renal Division and President, GelTex Pharmaceuticals. Prior to GelTex, he worked for several years at Merck & Co. across multiple roles in its hypertension and heart failure group and managed care division, and on its Vasotec and Prilosec products. Mr. Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School.
Timothy Noyes joined Proteon in 2006 as our President and Chief Executive Officer and has also been a member of our board of directors since joining the company. From 2002 to 2006, Mr. Noyes served as Chief Operating Officer of Trine Pharmaceuticals, Inc., a biopharmaceutical company. Before joining Trine, Mr. Noyes held several management positions with GelTex Pharmaceuticals from 1996 to 2001, prior to its acquisition by Genzyme Corporation. After the acquisition, from 2001 to 2002, he held the position of President, Renal Division and President, GelTex Pharmaceuticals. Prior to GelTex, he worked for several years at Merck & Co. across multiple roles in its hypertension and heart failure group and managed care division, and on its Vasotec and Prilosec products. Mr. Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School.
Steven Burke, M.D., joined Proteon in 2006 as our Senior Vice President and Chief Medical Officer. Prior to joining Proteon, Dr. Burke served as Senior Vice President of Medical and Regulatory Affairs and Vice President of Clinical Research at Genzyme Corporation, where he worked from 2000 to 2006. From 1994 to 2000, Dr. Burke held roles at GelTex Pharmaceuticals, including Vice President of Clinical Research and Medical Director, and before that he held positions at Glaxo. Dr. Burke received an A.B. from Harvard College and an M.D. from Cornell University Medical College. He completed a medical residency and fellowship at Brigham and Women’s Hospital and is certified by the American Board of Internal Medicine.
Steven Burke, M.D., joined Proteon in 2006 as our Senior Vice President and Chief Medical Officer. Prior to joining Proteon, Dr. Burke served as Senior Vice President of Medical and Regulatory Affairs and Vice President of Clinical Research at Genzyme Corporation, where he worked from 2000 to 2006. From 1994 to 2000, Dr. Burke held roles at GelTex Pharmaceuticals, including Vice President of Clinical Research and Medical Director, and before that he held positions at Glaxo. Dr. Burke received an A.B. from Harvard College and an M.D. from Cornell University Medical College. He completed a medical residency and fellowship at Brigham and Women’s Hospital and is certified by the American Board of Internal Medicine.
George Eldridge joined Proteon in 2013 as our Chief Financial Officer. Prior to joining Proteon, from 2009 to 2013, Mr. Eldridge served as a consultant to companies in the biotechnology industry, acting as a chief financial officer and providing advisory services. From 2006 to 2009, Mr. Eldridge was Chief Financial Officer of Targanta Therapeutics Corporation until its acquisition by The Medicines Company. Before working at Targanta, Mr. Eldridge served as Chief Financial Officer of Therion Biologics from 2002 to 2006, and prior to that he served as Chief Financial Officer of Curis (previously Ontogeny) and Boston Life Sciences. Prior to working in the biotechnology field, Mr. Eldridge was an investment banker at Kidder Peabody & Co. He holds a B.A. from Dartmouth College and an M.B.A. from the University of Chicago.
George Eldridge joined Proteon in 2013 as our Chief Financial Officer. Prior to joining Proteon, from 2009 to 2013, Mr. Eldridge served as a consultant to companies in the biotechnology industry, acting as a chief financial officer and providing advisory services. From 2006 to 2009, Mr. Eldridge was Chief Financial Officer of Targanta Therapeutics Corporation until its acquisition by The Medicines Company. Before working at Targanta, Mr. Eldridge served as Chief Financial Officer of Therion Biologics from 2002 to 2006, and prior to that he served as Chief Financial Officer of Curis (previously Ontogeny) and Boston Life Sciences. Prior to working in the biotechnology field, Mr. Eldridge was an investment banker at Kidder Peabody & Co. He holds a B.A. from Dartmouth College and an M.B.A. from the University of Chicago.
Scott Toner joined Proteon in 2015 as our Senior Vice President, Marketing. Prior to joining Proteon, from 2014 to 2015, Mr. Toner served as the VP Marketing and Sales of OPKO Health’s Renal Division. From 2013 to 2014, he served as a consultant to companies in the biotechnology industry and from 2011 to 2012 served as Senior Director, Marketing of Reata Pharmaceuticals. Prior to that, from 2007 to 2010, Mr. Toner served as Executive Director of Marketing with AMAG Pharmaceuticals. From 1985 to 2007, Mr. Toner held various roles within the domestic and international divisions of Abbott Laboratories, concentrating primarily on the nephrology and critical care therapeutic spaces. Mr. Toner holds a B.A. from Ithaca College and an M.B.A. from Drexel University.
Scott Toner joined Proteon in 2015 as our Senior Vice President, Marketing. Prior to joining Proteon, from 2014 to 2015, Mr. Toner served as the VP Marketing and Sales of OPKO Health’s Renal Division. From 2013 to 2014, he served as a consultant to companies in the biotechnology industry and from 2011 to 2012 served as Senior Director, Marketing of Reata Pharmaceuticals. Prior to that, from 2007 to 2010, Mr. Toner served as Executive Director of Marketing with AMAG Pharmaceuticals. From 1985 to 2007, Mr. Toner held various roles within the domestic and international divisions of Abbott Laboratories, concentrating primarily on the nephrology and critical care therapeutic spaces. Mr. Toner holds a B.A. from Ithaca College and an M.B.A. from Drexel University.
Daniel Gottlieb joined Proteon in 2007 and has served as our Vice President, Corporate Development since 2015, prior to which he was Vice President, Marketing and Business Development from 2013 until 2015, Senior Director of Marketing and Business Development from 2010 until 2013 and Director of Marketing and Business Development from 2007 until 2010. Prior to joining Proteon, Mr. Gottlieb served as Strategic Marketing Manager of Endovascular Products at Abbott Vascular from 2006 to 2007. Prior to that, Mr. Gottlieb spent seven years, from 1999 to 2006, at Guidant Corporation in a variety of roles, including marketing and market research, strategic planning, and business development and corporate venture investing as part of Guidant’s Compass Group. Mr. Gottlieb holds a B.A. from the University of Pennsylvania and an M.B.A. from the Tuck School of Business at Dartmouth College.
Daniel Gottlieb joined Proteon in 2007 and has served as our Vice President, Corporate Development since 2015, prior to which he was Vice President, Marketing and Business Development from 2013 until 2015, Senior Director of Marketing and Business Development from 2010 until 2013 and Director of Marketing and Business Development from 2007 until 2010. Prior to joining Proteon, Mr. Gottlieb served as Strategic Marketing Manager of Endovascular Products at Abbott Vascular from 2006 to 2007. Prior to that, Mr. Gottlieb spent seven years, from 1999 to 2006, at Guidant Corporation in a variety of roles, including marketing and market research, strategic planning, and business development and corporate venture investing as part of Guidant’s Compass Group. Mr. Gottlieb holds a B.A. from the University of Pennsylvania and an M.B.A. from the Tuck School of Business at Dartmouth College.
Pamela Gustafson joined Proteon in 2006 and has served as our Vice President, Clinical Research since 2015, prior to which she was the Senior Director of Clinical Research from 2012 until 2014 and Director of Clinical Research from 2006 until 2012. Prior to joining Proteon, Ms. Gustafson served as Director of Clinical Operations at Trine Pharmaceuticals from 2002 to 2006. Prior to that, Ms. Gustafson worked as a Project Manager at AAI International from 1999 until 2002, LeukoSite, Inc. from 1998 until 1999, and PAREXEL International from 1996 until 1998. Prior to PAREXEL, Ms. Gustafson spent ten years, from 1986 to 1996, in drug development positions at Alkermes, Seragen, Genzyme Corporation, and the Massachusetts Eye and Ear Infirmary. Ms. Gustafson holds a B.A. from Wheaton College and an M.P.H. from Boston University. Ms. Gustafson is also certified as a Project Management Professional.
Pamela Gustafson joined Proteon in 2006 and has served as our Vice President, Clinical Research since 2015, prior to which she was the Senior Director of Clinical Research from 2012 until 2014 and Director of Clinical Research from 2006 until 2012. Prior to joining Proteon, Ms. Gustafson served as Director of Clinical Operations at Trine Pharmaceuticals from 2002 to 2006. Prior to that, Ms. Gustafson worked as a Project Manager at AAI International from 1999 until 2002, LeukoSite, Inc. from 1998 until 1999, and PAREXEL International from 1996 until 1998. Prior to PAREXEL, Ms. Gustafson spent ten years, from 1986 to 1996, in drug development positions at Alkermes, Seragen, Genzyme Corporation, and the Massachusetts Eye and Ear Infirmary. Ms. Gustafson holds a B.A. from Wheaton College and an M.P.H. from Boston University. Ms. Gustafson is also certified as a Project Management Professional.
Matthew Kowalsky joined Proteon in 2016 as Vice President, Legal. Prior to joining Proteon, he served as Senior Corporate Counsel at Sanofi Genzyme from May 2015 to May 2016, supporting business development activities and marketed products for rare diseases. Mr. Kowalsky held the position of Associate General Counsel at Cubist Pharmaceuticals, Inc. from 2013 to 2015. He served as Assistant General Counsel at ARIAD Pharmaceuticals, Inc. in 2013 and Lantheus Medical Imaging, Inc. (formerly Bristol-Myers Squibb Medical Imaging, Inc.) from 2009 to 2013. Mr. Kowalsky began his legal career in the corporate and intellectual property groups of Choate, Hall & Stewart LLP. He holds a B.A. from the University of Notre Dame and a J.D. from the Notre Dame Law School. Before attending law school, he served as a surface warfare officer in the U.S. Navy.
Matthew Kowalsky joined Proteon in 2016 as Vice President, Legal. Prior to joining Proteon, he served as Senior Corporate Counsel at Sanofi Genzyme from May 2015 to May 2016, supporting business development activities and marketed products for rare diseases. Mr. Kowalsky held the position of Associate General Counsel at Cubist Pharmaceuticals, Inc. from 2013 to 2015. He served as Assistant General Counsel at ARIAD Pharmaceuticals, Inc. in 2013 and Lantheus Medical Imaging, Inc. (formerly Bristol-Myers Squibb Medical Imaging, Inc.) from 2009 to 2013. Mr. Kowalsky began his legal career in the corporate and intellectual property groups of Choate, Hall & Stewart LLP. He holds a B.A. from the University of Notre Dame and a J.D. from the Notre Dame Law School. Before attending law school, he served as a surface warfare officer in the U.S. Navy.
John Najim joined Proteon in 2009 and has served as our Vice President, Manufacturing and Process Development since 2015, prior to which he was the Senior Director of Manufacturing and Process Development from 2011 until 2014 and Director of Manufacturing from 2009 until 2011. Prior to joining Proteon, Mr. Najim served as Associate Director of Manufacturing at Dyax Corporation from 2004 to 2009. Prior to that, Mr. Najim spent six years, from 1998 to 2004, in a variety of roles at Johnson and Matthey, Genzyme Transgenics and Northeastern University, including manufacturing, process development, and research development. Mr. Najim holds a B.S. in Biochemistry from Merrimack College and an M.B.A. from the Graduate School of Business at Bentley University.
John Najim joined Proteon in 2009 and has served as our Vice President, Manufacturing and Process Development since 2015, prior to which he was the Senior Director of Manufacturing and Process Development from 2011 until 2014 and Director of Manufacturing from 2009 until 2011. Prior to joining Proteon, Mr. Najim served as Associate Director of Manufacturing at Dyax Corporation from 2004 to 2009. Prior to that, Mr. Najim spent six years, from 1998 to 2004, in a variety of roles at Johnson and Matthey, Genzyme Transgenics and Northeastern University, including manufacturing, process development, and research development. Mr. Najim holds a B.S. in Biochemistry from Merrimack College and an M.B.A. from the Graduate School of Business at Bentley University.
Bradley Hartman joined Proteon in 2018 as Vice President, People. Prior to joining Proteon, from 2016 to 2018, Mr. Hartman served as the Vice President of People for Unum Therapeutics where he oversaw all human resource functions and led the build out of the company from an early research stage to a publicly traded biotech with multiple programs in clinical development. Prior to that, from 2012 to 2016, Mr. Hartman served as Co-founder and Managing Partner of ConnectedSearch, a leading executive search firm focused on the biotech and pharmaceutical industries. Prior to ConnectedSearch, Mr. Hartman served in various human resource management roles at both Vertex Pharmaceuticals and Dyax Corporation. Mr. Hartman holds a B.S. from University of Rochester.
Bradley Hartman joined Proteon in 2018 as Vice President, People. Prior to joining Proteon, from 2016 to 2018, Mr. Hartman served as the Vice President of People for Unum Therapeutics where he oversaw all human resource functions and led the build out of the company from an early research stage to a publicly traded biotech with multiple programs in clinical development. Prior to that, from 2012 to 2016, Mr. Hartman served as Co-founder and Managing Partner of ConnectedSearch, a leading executive search firm focused on the biotech and pharmaceutical industries. Prior to ConnectedSearch, Mr. Hartman served in various human resource management roles at both Vertex Pharmaceuticals and Dyax Corporation. Mr. Hartman holds a B.S. from University of Rochester.
Marco Wong, M.D., Ph.D., joined Proteon in 2006 and has served as our Medical Director since 2011, prior to which he was Associate Director of Research and Development from 2009 until 2011 and Physician Scientist/Senior Scientist from 2006 until 2009. Prior to joining Proteon, Dr. Wong served as a Post-doctoral Research Associate at the Stowers Institute for Medical Research from 2003 to 2006, where he conducted genetic and molecular analysis of stem cells and germ cell development. He holds a B.S. from California State University and an M.D. and Ph.D. from Wayne State University School of Medicine.
Marco Wong, M.D., Ph.D., joined Proteon in 2006 and has served as our Medical Director since 2011, prior to which he was Associate Director of Research and Development from 2009 until 2011 and Physician Scientist/Senior Scientist from 2006 until 2009. Prior to joining Proteon, Dr. Wong served as a Post-doctoral Research Associate at the Stowers Institute for Medical Research from 2003 to 2006, where he conducted genetic and molecular analysis of stem cells and germ cell development. He holds a B.S. from California State University and an M.D. and Ph.D. from Wayne State University School of Medicine.
BOARD OF DIRECTORS
Paul Hastings has served as a member of our board of directors and its chairman since October 2016. Mr. Hastings is the Chief Executive Officer of Nkarta Inc. Prior to joining Nkarta Inc., Mr. Hastings was CEO and Chairman of Oncomed Pharmaceuticals. Prior to that, he served as President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President of Worldwide Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche. Mr. Hastings was Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2010), and served on the boards of ViaCell (sold to Perkin-Elmer in 2007), Cerimon Pharmaceuticals and Relypsa (sold to Galenica in 2016). He is currently on the board of Pacira Pharmaceuticals, serves as Vice Chairman of Biotechnology Innovation Organization, and is also on the board of directors of the California Life Sciences Association. Mr. Hastings received a B.S. in pharmacy from the University of Rhode Island.
Paul Hastings has served as a member of our board of directors and its chairman since October 2016. Mr. Hastings is the Chief Executive Officer of Nkarta Inc. Prior to joining Nkarta Inc., Mr. Hastings was CEO and Chairman of Oncomed Pharmaceuticals. Prior to that, he served as President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President of Worldwide Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche. Mr. Hastings was Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2010), and served on the boards of ViaCell (sold to Perkin-Elmer in 2007), Cerimon Pharmaceuticals and Relypsa (sold to Galenica in 2016). He is currently on the board of Pacira Pharmaceuticals, serves as Vice Chairman of Biotechnology Innovation Organization, and is also on the board of directors of the California Life Sciences Association. Mr. Hastings received a B.S. in pharmacy from the University of Rhode Island.
Timothy Noyes joined Proteon in 2006 as our President and Chief Executive Officer and has also been a member of our board of directors since joining the company. From 2002 to 2006, Mr. Noyes served as Chief Operating Officer of Trine Pharmaceuticals, Inc., a biopharmaceutical company. Before joining Trine, Mr. Noyes held several management positions with GelTex Pharmaceuticals from 1996 to 2001, prior to its acquisition by Genzyme Corporation. After the acquisition, from 2001 to 2002, he held the position of President, Renal Division and President, GelTex Pharmaceuticals. Prior to GelTex, he worked for several years at Merck & Co. across multiple roles in its hypertension and heart failure group and managed care division, and on its Vasotec and Prilosec products. Mr. Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School.
Timothy Noyes joined Proteon in 2006 as our President and Chief Executive Officer and has also been a member of our board of directors since joining the company. From 2002 to 2006, Mr. Noyes served as Chief Operating Officer of Trine Pharmaceuticals, Inc., a biopharmaceutical company. Before joining Trine, Mr. Noyes held several management positions with GelTex Pharmaceuticals from 1996 to 2001, prior to its acquisition by Genzyme Corporation. After the acquisition, from 2001 to 2002, he held the position of President, Renal Division and President, GelTex Pharmaceuticals. Prior to GelTex, he worked for several years at Merck & Co. across multiple roles in its hypertension and heart failure group and managed care division, and on its Vasotec and Prilosec products. Mr. Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School.
Hubert Birner, Ph.D., has served as a member of our board of directors since 2007. Dr. Birner is the managing partner of TVM Capital, a venture capital firm, which he joined in 2000. Before joining TVM Capital, Dr. Birner served as Head of Business Development Europe and Director of Marketing for Germany at Zeneca from 1998 to 2000. Dr. Birner joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice where he worked from 1995 to 1998. From 1992 to 1994, Dr. Birner was an Assistant Professor for biochemistry at the Ludwig-Maximilian-University in Munich. Dr. Birner currently serves as Chairman of the Board of Argos Therapeutics Inc., a publicly traded company, and also serves as Chairman of the Board of Spepharm Holding BV, NOXXON Pharma AG Berlina and leon-nanodrugs, all private companies. Dr. Birner previously served as a member of the board of directors of Horizon Pharma, Evotec AG, Probiodrug AG and BioXell SPA. Dr. Birner received an M.B.A. from Harvard Business School and a Ph.D. in biochemistry from Ludwig-Maximilian-University Munich, where he graduated summa cum laude.
Hubert Birner, Ph.D., has served as a member of our board of directors since 2007. Dr. Birner is the managing partner of TVM Capital, a venture capital firm, which he joined in 2000. Before joining TVM Capital, Dr. Birner served as Head of Business Development Europe and Director of Marketing for Germany at Zeneca from 1998 to 2000. Dr. Birner joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice where he worked from 1995 to 1998. From 1992 to 1994, Dr. Birner was an Assistant Professor for biochemistry at the Ludwig-Maximilian-University in Munich. Dr. Birner currently serves as Chairman of the Board of Argos Therapeutics Inc., a publicly traded company, and also serves as Chairman of the Board of Spepharm Holding BV, NOXXON Pharma AG Berlina and leon-nanodrugs, all private companies. Dr. Birner previously served as a member of the board of directors of Horizon Pharma, Evotec AG, Probiodrug AG and BioXell SPA. Dr. Birner received an M.B.A. from Harvard Business School and a Ph.D. in biochemistry from Ludwig-Maximilian-University Munich, where he graduated summa cum laude.
Garen Bohlin has served as a member of our board of directors since 2014. Since May 2012, Mr. Bohlin has served as a consultant to various life sciences and healthcare companies. From January 2010 until April 2012, he served as Executive Vice President of Constellation Pharmaceuticals, a biopharmaceutical company. Prior to joining Constellation Pharmaceuticals, Mr. Bohlin served as Chief Operating Officer of Sirtris Pharmaceuticals, a biopharmaceutical company, from January 2006 to December 2009. Mr. Bohlin was the founding Chief Executive Officer of Syntonix Pharmaceuticals, Inc., a biopharmaceutical company, from 1999 through December 2005. Earlier in his career, he held multiple executive positions at Genetics Institute, Inc., a biopharmaceutical company, and was a partner at Arthur Andersen & Co., a public accounting and consulting organization. Mr. Bohlin currently serves on the board of directors of Tetraphase Pharmaceuticals, Inc., Karyopharm Therapeutics Inc. and Collegium Pharmaceutical, Inc., all NASDAQ listed. He also served on the board of directors for Acusphere, Inc. from 2005 to January 2015, Praecis Pharmaceuticals, Inc. from 2005 to 2007, Targanta Therapeutics from 2007 to 2009, SpringLeaf Therapeutics from 2010 to 2013 and Precision Dermatology from 2012 to 2014. Mr. Bohlin received his B.S. in accounting and finance from The University of Illinois.
Garen Bohlin has served as a member of our board of directors since 2014. Since May 2012, Mr. Bohlin has served as a consultant to various life sciences and healthcare companies. From January 2010 until April 2012, he served as Executive Vice President of Constellation Pharmaceuticals, a biopharmaceutical company. Prior to joining Constellation Pharmaceuticals, Mr. Bohlin served as Chief Operating Officer of Sirtris Pharmaceuticals, a biopharmaceutical company, from January 2006 to December 2009. Mr. Bohlin was the founding Chief Executive Officer of Syntonix Pharmaceuticals, Inc., a biopharmaceutical company, from 1999 through December 2005. Earlier in his career, he held multiple executive positions at Genetics Institute, Inc., a biopharmaceutical company, and was a partner at Arthur Andersen & Co., a public accounting and consulting organization. Mr. Bohlin currently serves on the board of directors of Tetraphase Pharmaceuticals, Inc., Karyopharm Therapeutics Inc. and Collegium Pharmaceutical, Inc., all NASDAQ listed. He also served on the board of directors for Acusphere, Inc. from 2005 to January 2015, Praecis Pharmaceuticals, Inc. from 2005 to 2007, Targanta Therapeutics from 2007 to 2009, SpringLeaf Therapeutics from 2010 to 2013 and Precision Dermatology from 2012 to 2014. Mr. Bohlin received his B.S. in accounting and finance from The University of Illinois.
Scott A. Canute has served as a member of our board of directors since July 2015. Mr. Canute served as President of Global Manufacturing and Corporate Operations at Genzyme Corporation from 2010 until 2011. Prior to joining Genzyme, Mr. Canute spent 25 years at Eli Lilly and Company and served as President, Global Manufacturing Operations from 2004 until 2007. Mr. Canute currently serves as a member of the board of directors of Flexion Therapeutics, Inc., Akebia Therapeutics, Inc. and Immunomedics, Inc., and as a member of the technology advisory board of Moderna Therapeutics. He also served on the board of directors of AlloCure Inc., Inspiration Biopharmaceuticals Inc., Oncobiologics, Inc., and the National Association of Manufacturers and the Indiana Manufacturers Association. Mr. Canute earned a B.S. in chemical engineering from the University of Michigan and an M.B.A. from Harvard Business School.
Scott A. Canute has served as a member of our board of directors since July 2015. Mr. Canute served as President of Global Manufacturing and Corporate Operations at Genzyme Corporation from 2010 until 2011. Prior to joining Genzyme, Mr. Canute spent 25 years at Eli Lilly and Company and served as President, Global Manufacturing Operations from 2004 until 2007. Mr. Canute currently serves as a member of the board of directors of Flexion Therapeutics, Inc., Akebia Therapeutics, Inc. and Immunomedics, Inc., and as a member of the technology advisory board of Moderna Therapeutics. He also served on the board of directors of AlloCure Inc., Inspiration Biopharmaceuticals Inc., Oncobiologics, Inc., and the National Association of Manufacturers and the Indiana Manufacturers Association. Mr. Canute earned a B.S. in chemical engineering from the University of Michigan and an M.B.A. from Harvard Business School.
John G. Freund, M.D., became a member of our board of directors in 2014. Dr. Freund co-founded Skyline Ventures, a venture capital firm, in 1997, where he has served as a partner since its founding. Prior to founding Skyline, Dr. Freund served as managing director in the private equity group of Chancellor Capital Management from 1995 to 1997. In 1995, he co-founded Intuitive Surgical, Inc. and served on its board of directors until 2000. From 1988 to 1994, Dr. Freund served in various positions at Acuson Corporation, now part of Siemens, most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988, Dr. Freund worked at Morgan Stanley & Co., where he co-founded the Healthcare Group in the Corporate Finance Department. Dr. Freund currently serves as a member of the board of directors of Collegium Pharmaceutical, Inc. and Tetraphase Pharmaceuticals, Inc. He also previously served on the board of directors of four publicly traded companies, Map Pharmaceuticals, a biopharmaceutical company, Mako Surgical Corp., a medical device company, Concert Pharmaceuticals, Inc., a biopharmaceutical company and was Chairman of XenoPort, Inc., a biopharmaceutical company. He also serves on the board of directors of six U.S. registered investment funds managed by affiliates of the Capital Group, Inc. He is a member of the Advisory Board for the Harvard Business School Healthcare Initiative. He received an A.B. in history from Harvard College, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School, where he was a Baker Scholar and won the Loeb Fellowship in Finance.
John G. Freund, M.D., became a member of our board of directors in 2014. Dr. Freund co-founded Skyline Ventures, a venture capital firm, in 1997, where he has served as a partner since its founding. Prior to founding Skyline, Dr. Freund served as managing director in the private equity group of Chancellor Capital Management from 1995 to 1997. In 1995, he co-founded Intuitive Surgical, Inc. and served on its board of directors until 2000. From 1988 to 1994, Dr. Freund served in various positions at Acuson Corporation, now part of Siemens, most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988, Dr. Freund worked at Morgan Stanley & Co., where he co-founded the Healthcare Group in the Corporate Finance Department. Dr. Freund currently serves as a member of the board of directors of Collegium Pharmaceutical, Inc. and Tetraphase Pharmaceuticals, Inc. He also previously served on the board of directors of four publicly traded companies, Map Pharmaceuticals, a biopharmaceutical company, Mako Surgical Corp., a medical device company, Concert Pharmaceuticals, Inc., a biopharmaceutical company and was Chairman of XenoPort, Inc., a biopharmaceutical company. He also serves on the board of directors of six U.S. registered investment funds managed by affiliates of the Capital Group, Inc. He is a member of the Advisory Board for the Harvard Business School Healthcare Initiative. He received an A.B. in history from Harvard College, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School, where he was a Baker Scholar and won the Loeb Fellowship in Finance.
Tim Haines has served as a member of our board of directors since 2014. Mr. Haines joined Abingworth in 2005 and is currently Managing Partner. From 2000 to 2005, he was Chief Executive of Astex Therapeutics, an Abingworth portfolio company. From 1993 to 2000, Mr. Haines was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Current and past board positions include Astex Pharmaceuticals, Chroma, Fovea, Pixium Vision, PowderMed, Kspine, Stanmore Implants, Lombard Medical, Sientra, and Median Technologies. Mr. Haines received a B.Sc. from Exeter University and an M.B.A. from INSEAD. Mr. Haines is a former Director of the BIA and sat on the BVCA Venture Committee and the Wellcome Trust / NHS Health Innovation Challenge Fund.
Tim Haines has served as a member of our board of directors since 2014. Mr. Haines joined Abingworth in 2005 and is currently Managing Partner. From 2000 to 2005, he was Chief Executive of Astex Therapeutics, an Abingworth portfolio company. From 1993 to 2000, Mr. Haines was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Current and past board positions include Astex Pharmaceuticals, Chroma, Fovea, Pixium Vision, PowderMed, Kspine, Stanmore Implants, Lombard Medical, Sientra, and Median Technologies. Mr. Haines received a B.Sc. from Exeter University and an M.B.A. from INSEAD. Mr. Haines is a former Director of the BIA and sat on the BVCA Venture Committee and the Wellcome Trust / NHS Health Innovation Challenge Fund.
Tony Kingsley has served as a member of our board of directors since October 2015. Mr. Kingsley served as President and Chief Operating Officer at The Medicines Company (MDCO) from May 2016 to December 2017. Previously, he served as Executive Vice President, Global Commercial Operations at Biogen from November 2011 to October 2015. From January 2010 to November 2011, Mr. Kingsley served as Biogen's Senior Vice President, U.S. Commercial Operations. Prior to that, he served as Senior Vice President and General Manager of the Gynecological Surgical Products business at Hologic, Inc., from October 2007 to November 2009, and as Division President, Diagnostic Products at Cytyc Corp., from July 2006 to October 2007. From 1991 to 2006, he was a Partner at McKinsey & Company, focusing on the biotechnology, pharmaceutical and medical device industries. Mr. Kingsley received a B.A. in government from Dartmouth College and an M.B.A. from Harvard Business School.
Tony Kingsley has served as a member of our board of directors since October 2015. Mr. Kingsley served as President and Chief Operating Officer at The Medicines Company (MDCO) from May 2016 to December 2017. Previously, he served as Executive Vice President, Global Commercial Operations at Biogen from November 2011 to October 2015. From January 2010 to November 2011, Mr. Kingsley served as Biogen's Senior Vice President, U.S. Commercial Operations. Prior to that, he served as Senior Vice President and General Manager of the Gynecological Surgical Products business at Hologic, Inc., from October 2007 to November 2009, and as Division President, Diagnostic Products at Cytyc Corp., from July 2006 to October 2007. From 1991 to 2006, he was a Partner at McKinsey & Company, focusing on the biotechnology, pharmaceutical and medical device industries. Mr. Kingsley received a B.A. in government from Dartmouth College and an M.B.A. from Harvard Business School.
Jonathan Leff has served as a member of our board of directors since August 2017. Mr. Leff is a Partner of Deerfield Management Company, L.P. and Chairman of the Deerfield Institute. He joined Deerfield in 2013, and focuses on venture capital and structured investments in biotechnology and pharmaceuticals. Prior to joining Deerfield, for more than sixteen years, Mr. Leff was with Warburg Pincus, where he led the firm's investment efforts in biotechnology and pharmaceuticals. Mr. Leff has also been active in public policy discussions related to healthcare and medical innovation. He is a member of several not-for-profit Boards, including the Spinal Muscular Atrophy Foundation, Friends of Cancer Research, the Reagan-Udall Foundation for the Food and Drug Administration and the Columbia University Medical Center Board of Advisors. In addition, he previously served as a member of the Board of Directors of the Biotechnology Innovation Organization and a member of the Executive Committee of the Board of the National Venture Capital Association (NVCA). Previously he led NVCA's life sciences industry efforts as Chair of NVCA's Medical Innovation and Competitiveness Coalition (NVCA-MedIC). Mr. Leff received his A.B. from Harvard University, and earned his M.B.A. from The Stanford University Graduate School of Business.
Jonathan Leff has served as a member of our board of directors since August 2017. Mr. Leff is a Partner of Deerfield Management Company, L.P. and Chairman of the Deerfield Institute. He joined Deerfield in 2013, and focuses on venture capital and structured investments in biotechnology and pharmaceuticals. Prior to joining Deerfield, for more than sixteen years, Mr. Leff was with Warburg Pincus, where he led the firm's investment efforts in biotechnology and pharmaceuticals. Mr. Leff has also been active in public policy discussions related to healthcare and medical innovation. He is a member of several not-for-profit Boards, including the Spinal Muscular Atrophy Foundation, Friends of Cancer Research, the Reagan-Udall Foundation for the Food and Drug Administration and the Columbia University Medical Center Board of Advisors. In addition, he previously served as a member of the Board of Directors of the Biotechnology Innovation Organization and a member of the Executive Committee of the Board of the National Venture Capital Association (NVCA). Previously he led NVCA's life sciences industry efforts as Chair of NVCA's Medical Innovation and Competitiveness Coalition (NVCA-MedIC). Mr. Leff received his A.B. from Harvard University, and earned his M.B.A. from The Stanford University Graduate School of Business.
